Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.460
-0.130 (-5.02%)
At close: Mar 5, 2026, 4:00 PM EST
2.400
-0.060 (-2.44%)
After-hours: Mar 5, 2026, 7:17 PM EST
CNTB Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CNTB stock have an average target of 8.50, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 245.53% from the current stock price of 2.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 1, 2025.
Analyst Ratings
The average analyst rating for CNTB stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +265.85% | Dec 1, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +306.50% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +306.50% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +184.55% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +184.55% | Jun 12, 2025 |
Financial Forecast
Revenue This Year
299.21K
from 26.03M
Decreased by -98.85%
Revenue Next Year
73.96M
from 299.21K
Increased by 24,617.69%
EPS This Year
-4.92
from -0.28
EPS Next Year
-3.92
from -4.92
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 746,760 | 152.3M | ||||
| Avg | 299,207 | 74.0M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -97.1% | 50,787.9% | ||||
| Avg | -98.9% | 24,617.7% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.05 | -0.89 | ||
| Avg | -4.92 | -3.92 | ||
| Low | -7.28 | -7.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.